Athena Diagnostics

NAbFeron (IFN-b) Antibody Test

athena diagnostics®

Testing that Makes a Difference.

Patient		Requesting Physician	Accession Number
REPORT, SAMPLE			12345678
Date of Birth	Sex	Report to	Family Number/Kindred Number
04/15/1983	M	QUEST DIAGNOSTICS	
Specimen Type		Address	Patient Number
Serum		200 FOREST STREET	00000000
Test Category			Specimen Collection Date
Diagnostic (Symptomatic)		2ND FLOOR	11/29/2019
Test Requested			Date Received
NAbFeron (IFN-b) Antibody Test		MARLBOROUGH, MA 01752	12/01/2019
		Additional Reports to:	Report Date
			12/06/2019

NAbFeron (IFN-b) Antibody Test

This analysis did not detect an elevated level of neutralizing antibodies (NAbs) to human interferon (IFN) beta.

INTERPRETIVE RESULTS TABLE

	Test	Technical Result	Reference Range
Not Elevated	**NAbs to IFN beta**	**<1:20**	**not elevated <1:20, mild/moderatly elevated 1:20-1:100, highly elevated >1:100**

Recommendations: Health care providers, please contact the Athena Diagnostics Client Services Department at 1-800-394-4493 if you wish to speak with a clinical consultant regarding this test result.

Background information: The presence of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with a reduction in the clinical effectiveness of interferon beta therapy (1). Although the measurement of NAbs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history (2, 3).

Methods:
Detection of antibodies was performed using a viral cytopathic effect bioassay.

Limitations of analysis: Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

Background References

1. Goodin, DS, et al. (2007) Neurology 68:977-984 (PMID:17389300)
2. Polman, CH, et al. (2010) Lancet Neurol 9:740-50 (PMID:20610349)
3. Creeke, PI, et al. (2013) Ther Adv Neurol Disord 6:3-17 (PMID:23277789)

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA license holder, Athena Diagnostics (CLIA# 22D0069726)